Navigation Links
Neurologix Announces First Quarter 2011 Financial Results
Date:5/13/2011

FORT LEE, N.J., May 13, 2011 /PRNewswire/ -- Neurologix, Inc. (OTCBB: NRGX), a biotechnology company engaged in the development of innovative gene therapies for disorders of the brain and central nervous system, today announced its financial results for the three months ended March 31, 2011.

For the three months ended March 31, 2011, Neurologix reported a net loss of $2.1 million, as compared with a net loss of $3.5 million for the three months ended March 31, 2010. The Company reported a net loss applicable to common stock for the three months ended March 31, 2011 of $2.9 million, or $0.10 per basic and diluted share, as compared with a net loss applicable to common stock for the three months ended March 31, 2010 of $4.3 million, or $0.15 per basic and diluted share.

Net loss for the three months ended March 31, 2011 includes other income of $1.3 million recognized for the change in estimated fair value of the Company's derivative liabilities relating to certain warrants issued in connection with promissory notes issued by the Company in December 2010 (the "Notes"), as well as the Company's Series D Convertible Preferred Stock (the "Series D Stock") and the Company's Series C Convertible Preferred Stock (the "Series C Stock").  The first quarter 2011 net loss also includes interest expense related to the Notes of $1.4 million.

Net loss for the three months ended March 31, 2010 included charges of $0.4 million recognized for the change in estimated fair value of the Company's derivative liabilities relating to warrants issued in connection with the Series D Stock and the Series C Stock.

Net loss applicable to common stock for the three months ended March 31, 2011 includes charges of $0.8 million, or $0.03 per basic and diluted share, related to preferred stock dividends in connection with the Series D Stock and the Series C Stock. The net loss applicable to common stock for the three months ended March 31, 2010 included ch
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
3. Neurologix Reports Third Quarter 2010 Financial Results
4. Neurologix Completes Additional $7 Million Financing
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... NEW YORK , March 30, 2015  Check-Cap ... diagnostics company focused on the development of a preparation-free ... screening for colorectal cancer, announced today that its CEO, ... the March 31, 2015 trading day.  Neev and Check-Cap ... to commemorate the company,s initial public offering and simultaneous ...
(Date:3/30/2015)... and ORANGEBURG, N.Y., March 30, 2015 /PRNewswire/ ... (NASDAQ: VSCI ) shareholders have voted at ... today to approve the previously announced agreement and ... "We are pleased with the outcome of ... thank both shareholder groups for approving the merger ...
(Date:3/30/2015)... , March 30, 2015  Rigrodsky & Long, P.A.: ... (NASDAQ GM: ASPX )? , Did you purchase ... , Do you think the proposed buyout price is too ... Rigrodsky & Long, P.A. announces ... of directors of Auspex Pharmaceuticals, Inc. ("Auspex" or the "Company") ...
Breaking Medicine Technology:Check-Cap to Celebrate Initial Public Offering with NASDAQ Closing Bell Ceremony on March 31, 2015 2Check-Cap to Celebrate Initial Public Offering with NASDAQ Closing Bell Ceremony on March 31, 2015 3Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 2Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 3Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 4AUSPEX PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout 2
... Brain Resource, Ltd., (BRRZY: OTC US, BRC: ASX), developer of ... a personal heart rate monitor for managing stress, at Health 2.0 ... slow breathing at a personal best breathing rate. ... the best ways to decrease stress, but not many people know ...
... 27, 2011 Kinerase, an icon of scientific skincare development, ... in a row.  The Kinerase Restructure Firming ... 2011 Allure Best of Beauty Awards, appearing in the magazine,s ... This year, over 236 beauty products were chosen ...
Cached Medicine Technology:Brain Resource Launches MyCalmBeat Personal Stress Reduction Monitor at Health 2.0 2Brain Resource Launches MyCalmBeat Personal Stress Reduction Monitor at Health 2.0 3Kinerase Wins Allure Best of Beauty Award for 2nd Consecutive Year 2
(Date:3/30/2015)... On March 27th, 2015, 24Hr HomeCare ... inspire courage in Seth Lane, a five-year-old boy from ... SCID causes affected individuals to be susceptible to life-threatening ... allow the development of functional immune systems. Lane, ... video with his family requesting its viewers to wear ...
(Date:3/30/2015)... March 30, 2015 GenSight ®, ... is named as a leader in The Forrester Wave™: ... 2015 report. , The independent report positions GenSight as ... possible (5 out of 5) for the analytics, corporate ... which contributed to GenSight’s position in the Leaders category. ...
(Date:3/30/2015)... 2015 V/NO (Virtually No Alcohol) Wines have ... for opening/closing and for reuse. Consumers simply twist the cup, ... New Yorkers, professionals, and basically anyone can now enjoy a ... kick back socially or pair with meals at work, home, ... dealcoholized wine and that means Napa Wine grapes undergo ...
(Date:3/30/2015)... The “Orthopedic Software Market [By ... By Applications (Orthopedic Surgery, Joint Replacement, Fracture ... – Global Forecast to 2020” analyzes and ... in North America, Europe, Asia-Pacific and the ... before Buying: http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=94720371 , This ...
(Date:3/30/2015)... TX (PRWEB) March 30, 2015 ... been Drummond Certified™ in the second AS4 test ... Inc., the trusted leader in interoperability software testing. ... Oracle and Software AG participated in this vendor-neutral ... represents the first AS4 interoperability certifications for IBM, ...
Breaking Medicine News(10 mins):Health News:24Hr HomeCare Staff Hosts #WearYellowForSeth Campaign for Five-Year-Old Boy with Severe Combined Immunodeficiency 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 3Health News:Napa Valley Alcohol-Removed Red, White & Rosé Wines Have Launched. 2Health News:The Global Orthopedic Software Market is Expected to Reach $308.5 Million by 2020 – Report Published by MarketsandMarkets 2Health News:The Global Orthopedic Software Market is Expected to Reach $308.5 Million by 2020 – Report Published by MarketsandMarkets 3Health News:The Global Orthopedic Software Market is Expected to Reach $308.5 Million by 2020 – Report Published by MarketsandMarkets 4Health News:Latest AS4 Standard-Based Products Drummond Certified™ 2Health News:Latest AS4 Standard-Based Products Drummond Certified™ 3
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, Dec. ... urged the agency to take a new look at data ... include mercury. The FDA had ruled in 2009 that ... "We need to see where the science is and if ...
... HealthDay Reporter , THURSDAY, Dec. 16 (HealthDay News) ... missing amygdala -- the part of the brain believed ... help improve treatment for post-traumatic stress disorder (PTSD) ... human study confirming that the almond-shaped structure is crucial ...
... children, their families, artists and scientists in a first ... symbiosis was established between several groups in society, leading ... Ferreira, group leader at the Instituto Gulbenkian de Cincia, ... the 10,000 euros Simbiontes Award, for his proposal to ...
... NY, December 15, 2010 There is burgeoning public ... including cardiovascular health. In a study published in the ... Medicine, investigators found that there was no independent ... hormone and cardiovascular mortality in this prospective study, the ...
... WEDNESDAY, Dec. 15 (HealthDay News) -- In a rare case, a ... longer has any detectable HIV cells in his blood following a ... But experts were quick to caution that the case does not ... As it turns out, the donor for that transplant carried a ...
... WEDNESDAY, Dec. 15 (HealthDay News) -- A ban on drop-side ... of recalls and the deaths of more than 30 infants ... by the U.S. Consumer Product Safety Commission forbids the manufacture, ... rail that moves up and down. The requirement that all ...
Cached Medicine News:Health News:FDA Panel Calls for Safety Review of Mercury in Dental Fillings 2Health News:FDA Panel Calls for Safety Review of Mercury in Dental Fillings 3Health News:Brain Anomaly Leaves Woman Without Fear 2Health News:Brain Anomaly Leaves Woman Without Fear 3Health News:Instituto Gulbenkian de Ciencia scientist wins new Portuguese award Simbiontes for cancer research 2Health News:Vitamin D and parathyroid hormone levels may not affect cardiovascular mortality 2Health News:Docs Claim Transplant Cured Man of HIV, But Experts Urge Caution 2Health News:Docs Claim Transplant Cured Man of HIV, But Experts Urge Caution 3Health News:U.S. Government Bans Drop-Side Cribs 2
... Roches patented polymerase chain reaction (PCR) technology, ... is an essential component of Roches blood ... allows minute amounts of selected unique regions ... billions of copies (that is, to detectable ...
... Continuing to lead the market in ... WAVE IABP is a whole new first ... optic technology coupled with a physiologically based ... support with unprecedented timing accuracy. Second ...
... NexES IHC, the worlds first ... staining system introduced a whole ... while combining system modularity and ... laboratory productivity. The NexES Systems ...
... a nonprofit, physician-directed organization promoting quality ... care through programs of voluntary education, ... professionals in all sizes of medical ... accreditation, quality management services, consultation in ...
Medicine Products: